Healius Ltd (ASX: HLS) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Healius Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $2.90 billion
P/E Ratio 43.48
Dividend Yield 2.85%
Shares Outstanding 623.16 million
Earnings per share 0.107
Dividend per share 0.14
Year To Date Return 28.22%
Earnings Yield 2.30%
Franking 100%
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

Should you invest $1,000 in right now?

Before you consider , you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

Healius Ltd (ASX: HLS)
Latest News

Dividend Payment History Data provided by Morningstar.

Data provided by Morningstar.
Ex-Date Amount Franking Type Payable
13 Sep 2021 $0.0675 100.00% Final 08 Oct 2021
25 Mar 2021 $0.0650 100.00% Interim 15 Apr 2021
26 Mar 2020 $0.0260 100.00% Interim 15 Oct 2020
29 Aug 2019 $0.0340 100.00% Final 27 Sep 2019
15 Mar 2019 $0.0380 100.00% Interim 26 Mar 2019
27 Aug 2018 $0.0550 100.00% Final 17 Sep 2018
16 Mar 2018 $0.0510 100.00% Interim 27 Mar 2018
31 Aug 2017 $0.0580 100.00% Final 18 Sep 2017
17 Mar 2017 $0.0480 100.00% Interim 28 Mar 2017
01 Sep 2016 $0.0640 100.00% Final 19 Sep 2016
18 Mar 2016 $0.0560 50.00% Interim 29 Mar 2016
26 Aug 2015 $0.1100 50.00% Final 14 Sep 2015
18 Mar 2015 $0.0900 100.00% Interim 07 Apr 2015
27 Aug 2014 $0.1100 100.00% Final 15 Sep 2014
17 Mar 2014 $0.0900 100.00% Interim 07 Apr 2014
16 Sep 2013 $0.1100 100.00% Final 08 Oct 2013
18 Mar 2013 $0.0650 100.00% Interim 08 Apr 2013
17 Sep 2012 $0.0600 100.00% Final 08 Oct 2012
26 Mar 2012 $0.0500 100.00% Interim 16 Apr 2012
19 Sep 2011 $0.0500 100.00% Final 10 Oct 2011
21 Mar 2011 $0.0300 100.00% Interim 11 Apr 2011
20 Sep 2010 $0.1000 100.00% Final 11 Oct 2010
05 Mar 2010 $0.1500 100.00% Interim 29 Mar 2010
07 Sep 2009 $0.0700 100.00% Final 28 Sep 2009
16 Feb 2009 $0.0700 100.00% Interim 09 Mar 2009

HLS ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
YesNo

About Healius Ltd

Healius Ltd (HLS) is an Australian healthcare company with operations in 3 main business segments: pathology, medical centres and imaging. On top of this, Healius also has 3 emerging business segments: dental, IVF and day hospitals.

With this, Healius provides diagnostic services to consumers and referring practitioners, and enables healthcare professionals to deliver patient care in partnership with the company’s nurses and support staff. Healius has a 13,000-strong workforce and a market-leading network consisting of pathology laboratories, collection centres, medical centres, day hospitals and imaging sites located throughout Australia.

Healius was formerly known as Primary Health Care and traded on the ASX under the ticker code PRY. In 2018, it rebranded as Healius to, according to the company, better align with its services, people and future.

HLS Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
15 Oct 2021 $4.65 $-0.02 -0.43% 2,383,220 $4.71 $4.72 $4.62
14 Oct 2021 $4.67 $-0.03 -0.64% 2,463,515 $4.75 $4.75 $4.66
13 Oct 2021 $4.70 $0.05 1.08% 2,041,937 $4.65 $4.80 $4.64
12 Oct 2021 $4.65 $-0.04 -0.85% 3,420,973 $4.60 $4.69 $4.56
11 Oct 2021 $4.69 $-0.13 -2.70% 2,342,981 $4.72 $4.78 $4.67
08 Oct 2021 $4.82 $0.04 0.84% 2,248,842 $4.83 $4.83 $4.73
07 Oct 2021 $4.78 $0.11 2.36% 2,298,287 $4.80 $4.82 $4.72
06 Oct 2021 $4.67 $0.01 0.21% 2,308,774 $4.70 $4.72 $4.65
05 Oct 2021 $4.66 $-0.06 -1.27% 2,114,493 $4.68 $4.75 $4.64
04 Oct 2021 $4.72 $0.00 0.00% 874,633 $4.75 $4.78 $4.69
01 Oct 2021 $4.72 $-0.08 -1.67% 2,419,886 $4.70 $4.72 $4.63
30 Sep 2021 $4.80 $0.09 1.91% 2,999,219 $4.75 $4.80 $4.72
29 Sep 2021 $4.71 $-0.09 -1.88% 2,105,954 $4.77 $4.78 $4.67
28 Sep 2021 $4.80 $-0.19 -3.81% 2,089,469 $4.88 $4.91 $4.78
27 Sep 2021 $4.99 $0.06 1.22% 2,805,144 $4.97 $5.01 $4.90
24 Sep 2021 $4.93 $-0.06 -1.20% 5,248,767 $4.97 $5.01 $4.91
23 Sep 2021 $4.99 $0.04 0.81% 3,892,251 $5.05 $5.05 $4.98
22 Sep 2021 $4.95 $0.02 0.41% 3,022,870 $4.93 $5.00 $4.92
21 Sep 2021 $4.93 $-0.05 -1.00% 2,768,191 $4.95 $4.96 $4.84
20 Sep 2021 $4.98 $0.04 0.81% 3,524,487 $4.93 $5.03 $4.92

Director Transactions Data provided by Morningstar.

Data provided by Morningstar.
Date Director Type Amount Value Notes
06 Sep 2021 Malcolm Parmenter Expiry 80 $402,490
As advised by the company. Performance Rights (80,498) lapsed.
06 Sep 2021 Malcolm Parmenter Issued 724 $3,622,410
Conversion of securities.
06 Sep 2021 Malcolm Parmenter Exercise 724 $3,622,410
Conversion of securities. 80,498 - Performance Rights
01 Sep 2021 Jennifer (Jenny) Macdonald Buy 10 $49,800
On-market trade.
01 Sep 2021 Jennifer (Jenny) Macdonald Buy 10 $49,900
On-market trade.
31 Aug 2021 Paul Jones Exercise 5 $19,999
Conversion of securities. Volume weighted average price
31 Aug 2021 Paul Jones Buy 5 $19,999
Conversion of securities. Volume weighted average price
31 Aug 2021 Robert Hubbard Exercise 14 $49,954
Conversion of securities. volume weighted average price
31 Aug 2021 Robert Hubbard Buy 14 $49,954
Conversion of securities. volume weighted average price
31 Aug 2021 Sally Evans Buy 7 $24,997
Conversion of securities. volume weighted average price
31 Aug 2021 Sally Evans Exercise 7 $24,997
Conversion of securities. volume weighted average price
26 Feb 2021 Kathryn (Kate) McKenzie Buy 2 $10,175
On-market trade.
25 Feb 2021 Sally Evans Buy 3 $12,498
Conversion of securities. VWAP
25 Feb 2021 Sally Evans Exercise 3 $12,498
Conversion of securities. 7,173 - Share Rights
VWAP
25 Feb 2021 Robert Hubbard Buy 7 $24,977
Conversion of securities. VWAP
25 Feb 2021 Robert Hubbard Exercise 7 $24,977
Conversion of securities. 14,346 - Share Rights
VWAP.
10 Dec 2020 Paul Jones Buy 2 $9,999
Conversion of securities. VWAP
10 Dec 2020 Paul Jones Exercise 2 $9,999
Conversion of securities. 5,738 - Share Rights
VWAP
10 Dec 2020 Paul Jones Issued 8 $30,000
Directors' share plan. 8,607 - Share Rights
VWAP
10 Dec 2020 Sally Evans Issued 10 $37,500
Directors' share plan. 10,759 - Share Rights
WVAP
10 Dec 2020 Robert Hubbard Issued 21 $75,000
Directors' share plan. 21,518 - Share Rights
VWAP
10 Nov 2020 Jennifer (Jenny) Macdonald Buy 15 $52,650
On-market trade.

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Mr Robert Hubbard Non-Executive DirectorNon-Executive Chairman Dec 2014
Mr Hubbard was a member of the Risk Management Committee up to that date. Rob Birmingham. He previously held partnership positions in the accounting, corporate finance, assurance and audit divisions of PricewaterhouseCoopers and acted as external auditor for some of Australia's largest ASX-listed companies.
Dr Malcolm Parmenter Chief Executive OfficerManaging Director Sep 2017
Dr Parmenter joined Healius as Managing Director and Chief Executive Officer (CEO) in September 2017. He has a wealth of knowledge and practical experience in the operation of frontline care, with over nine years' tenure as CEO of Independent Practitioner Network Limited (IPN), both as a listed company and under the ownership of Sonic Healthcare Limited, and subsequently two years as CEO of Sonic Clinical Services. He has a strong understanding of healthcare delivery, both in Australia and abroad, and has spent more than 20 years as a General Practitioner.
Mr Gordon Richard Davis Non-Executive Director Aug 2015
Mr Davis was appointed as a member of the Risk Management Committee and as Chair of the Risk Management Committee on 19 August 2019, at which time he ceased as Audit Committee Chair but remained a member of that committee. Prior to becoming a Non-executive Director, Gordon was Managing Director of AWB Limited between 2006 and 2010. He has also served in a senior capacity on various industry associations.
Dr Paul Francis Jones Non-Executive Director Nov 2010
Dr Jones was appointed as a Non-executive Director in November 2010. During FY 2021, he was a member of the Audit Committee (from 25 February 2021), the People & Governance Committee and the Risk Management Committee (the latter until 25 February 2021). He has over 35 years' experience in a broad range of general medical practice, including 15 years' experience in Healius Group medical centres. He originally trained at the Repatriation and General Hospital, Concord NSW and subsequently at Calvary Public Hospital, Bruce ACT. He has been a Director and Federal Councillor of the Australian Medical Association (AMA), a past President of AMA ACT and a member of the Federal AMA Council of General Practice. He was formerly a general practitioner adviser to Calvary Public Hospital and held roles as GPVMO and Director, Medical Education Program. He is a former Chair of ACT GP Workforce Working Group and was a member of the ACT Health Minister's GP Task Force in 2009
Ms Jennifer (Jenny) Mitchell Macdonald Non-Executive Director Nov 2020
Ms Macdonald was appointed as a Non-executive Director and Chair of the Audit Committee effective 3 November 2020. She has a strong background in financial and general management roles across a range of industry sectors including fast moving consumer goods, resources, travel and digital media. she commenced her career with KPMG, working in the London and Melbourne offices in a number of practice areas, including audit, she spent more than ten years with that firm. After gaining experience in the resources sector, she held executive roles in the travel and tourism industries and digital media at Flight Centre and REA Group. From 2014-2016 Jenny was the Chief Financial Officer and then Interim Chief Executive Officer of Helloworld, an ASX-listed multi-channel travel company.
Ms Kathryn (Kate) Mary McKenzie Non-Executive Director Feb 2021
Ms McKenzie was appointed as a Non-executive Director effective 25 February 2021. She was appointed as a member of the People & Governance Committee and as a member of the Risk Management Committee on the same date. She is a highly experienced Chief Executive Officer and Non-executive Director with experience in large change management. After starting her career in the public sector, she joined Telstra in 2004 as Group Managing Director Regulatory, Public Policy & Communications. In her 12 years at Telstra, she held a range of executive roles in strategy, marketing, products and wholesale. Prior to leaving Telstra, she was Chief Operating Officer, responsible for networks, IT, field services, property and NBN relations and delivery. In 2017 she was appointed Chief Executive Officer of Chorus, a New Zealand listed telecommunications company. She is passionate about innovation and technology, and co-founded muru-D, an incubator which has produced 44 graduating companies, with 41 still in operation; Gurrowa, a co-creation lab, and partnerships with universities, such as investment in Quantum Computing with the University of New South Wales
Ms Sally Evans Non-Executive Director Aug 2018
Ms Evans was appointed as a Non-executive Director in August 2018, also being appointed as a member of the Nomination and Remuneration Committee and the Risk Management Committee. On 19 August 2019, she was appointed as Chair of the newly renamed People & Governance Committee. Sally has over 30 years' experience in private, government and social enterprise sectors and has worked in Australia, New Zealand, the United Kingdom and Hong Kong with responsibilities across the broader Asia Pacific region. She has served as a Non-executive Director of Gateway Lifestyle Operations Limited.
Ms Alison Stephenson Company Secretary Aug 2019
-
Mr Charles Tilley Company Secretary Feb 2015
-
Dean Lewsam Chief Executive Imaging
-
John McKechnie Chief Executive Pathology
-
Maxine Jaquet Chief Financial Officer & Chief Operating Officer (CFO & COO)
-
Alison Stephenson Company Secretary
-
Charles Tilley Company Secretary
-

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
HSBC Custody Nominees (Australia) Limited 175,386,356 29.29%
Citicorp Nominees Pty Limited 112,031,380 18.71%
J P Morgan Nominees Australia Pty Limited 89,264,817 14.91%
National Nominees Pty Ltd 71,170,798 11.88%
BNP Paribas Nominees Pty Ltd <Agency Lending Drp A/C> 20,574,535 3.44%
Argo Investments Limited 16,320,664 2.73%
BNP Paribas Noms Pty Ltd <DRP> 11,463,079 1.91%
HSBC Custody Nominees (Australia) Limited <Nt Comnwlth Super Corp A/C> 10,184,406 1.70%
Cs Third Nominees Pty Limited <HSBC Cust Nom Au Ltd 13 A/C> 6,229,569 1.04%
Citicorp Nominees Pty Ltd <Colonial First State Inv A/C> 4,285,700 0.72%
RinRim Pty Ltd 2,392,047 0.40%
BNP Paribas Nominees Pty Ltd Six Sis Ltd <DRP A/C> 1,761,260 0.29%
UBS Nominees Pty Ltd 1,057,466 0.18%
HSBC Custody Nominees (Australia) Limited <GSCO Customer A/C> 997,257 0.17%
AMP Life Limited 811,628 0.14%
Bnp Paribas Nominees Pty Ltd Hub24 Custodial Serv Ltd <Drp A/C> 799,450 0.13%
Nulis Nominees (Australia) Limited <Navigator Mast Plan Sett A/C> 784,767 0.13%
Joromada Pty Ltd 710,000 0.12%
Navigator Australia Ltd <MLC Investment Sett A/C> 708,490 0.12%
Merrill Lynch (Australia) Nominees Pty Limited 695,511 0.12%

Profile

since

Note